Company / Shareholders' Equity
Gilead Sciences Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$22.7B
FY2025
5-year range
$19.3B / $22.8B
FY2021-FY2025
Trend
+17.4%
vs FY2024
Sector context
#6 of 213
Health Care
What the data says
Among 213 Health Care companies, Gilead Sciences is in the top 3% for shareholders' equity. Shareholders' Equity has fluctuated over the past 10 years, ranging from $18.2B in FY2020 to $22.8B in FY2023.
Based on SEC 10-K filings.
$22.7B in FY2025 with a 5-year CAGR of +4.5%. Top quartile in the Health Care sector.
Remained stable around $22.7B over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +2.2%
- 5-Year CAGR
- +4.5%
- 10-Year CAGR
- -
Sector benchmark
Top 3% in Health CareTop 3% of 213This company $22.7B Sector average $2.5B
▼
+790.7% above sector average
Key checks
Key Insights
- 5-year CAGR of +4.5%, indicating consistent growth.
- In FY2025, shareholders' equity increased 17.4% year-over-year.
- Ranks #6 out of 213 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2023.
Company context
Key Data Points
- Strong profit margin: 27.9%
- Strong return on equity: 37.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $22.7B | +17.4% |
| FY2024 | $19.3B | -15.3% |
| FY2023 | $22.8B | +7.5% |
| FY2022 | $21.2B | +0.8% |
| FY2021 | $21.1B | +15.8% |
| FY2020 | $18.2B | -19.2% |
| FY2019 | $22.5B | +5.3% |
| FY2018 | $21.4B | +4.6% |
| FY2017 | $20.4B | +8.2% |
| FY2016 | $18.9B | +1.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026